Cardiorenalmetabolic

Latest News
April 18th 2025

"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

April 12th 2025

Identifying Binge Eating Triggers Among Adults With Food Insecurity

April 9th 2025

Semaglutide Use Could Prevent Up to 2 Million MACE in 10 Years, Model Suggests

April 9th 2025

GLP-1 RAs, SGLT2 Inhibitors Associated With Reduced MACE, HHF in Patients With Diabetes

April 8th 2025

Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD

Video Interviews
View All
April 11th 2025

New Hope for IgA Nephropathy With Atrasentan Approval: Richard Lafayette, MD, FACP

April 10th 2025

Lp(a) Awareness Imperative for Enhancing Testing, Prevention Efforts in CVD: Joseph Saseen, PharmD

March 17th 2025

2025 GPBCH Employer Symposia Set to Address Cardiovascular, MSK Challenges

November 18th 2024

Innovations in Atherosclerosis Have Potential to Benefit Patients With CKD, HIV

September 5th 2024

Comprehensive Care: The Key to Managing Diabetes and Its Complexities

September 4th 2024

UPMC's Dr Manisha Jhamb Urges Better Kidney Disease Awareness, Integrated Care

August 2nd 2024

GLP-1 Agonists and the Gut-Brain Axis: A New Era in Obesity Management

July 8th 2024

2024 ASPC Congress on CVD Prevention to Be Held in August

June 15th 2024

Dr Kathryn Lindley Addresses Barriers to Women’s Heart Disease Diagnosis

Podcasts
View All
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

October 22nd 2024

Engage, Educate, Empower: Transforming Kidney Care

More News

AJMC
April 7th 2025

The Role of Advanced Technologies in Improving Diabetes Outcomes

David G. Marrero, PhD Christopher G. Parkin, MS Grazia Aleppo, MD Irl B. Hirsch, MD Janet McGill, MD, MA Rodolfo J. Galindo, MD Davida F. Kruger, MSN, APRN-BC, BC-ADM Carol J. Levy, MD, CDE Anders L. Carlson, MD Guillermo E. Umpierrez, MD, CDE
This article reviews underlying barriers to health care access and discusses how a value-based diabetes care model could improve patient outcomes and reduce long-term costs.
AJMC
April 3rd 2025

Combined Effect of Continuous Glucose Monitoring and Semaglutide: Analysis of Administrative Claims

Poorva M. Nemlekar, MS Katia L. Hannah, PhD, MPH Courtney R. Green, PhD Thomas Grace, MD Peter M. Lynch, MPH Jessica R. Castle, MD Gregory J. Norman, PhD
Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone.
Kidney | Image credit: Crystal light - stock.adobe.com
April 3rd 2025

FDA Approves Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy

Julia Bonavitacola
Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary immunoglobulin A (IgA) nephropathy.
Continuous glucose monitor. | Image credit: Pixel-Shot – stock.adobe.com
March 26th 2025

CGM Adherence and Costs Improve With DME Channel Over Pharmacy

Hayden E. Klein
A real-world analysis showed a link between continuous glucose monitor (CGM) distribution channel and outcomes for patients with diabetes.
The investigators concluded that epidemiological inequity in CKD and cardiovascular disease remains an important issue that requires further study of potential interventions. | Image credit: filins - stock.adobe.com
March 22nd 2025

Disparities in CKD-Associated Cardiac Arrest Across Demographics

Jared Kaltwasser
Non-Hispanic Black populations face the highest risk of death from chronic kidney disease (CKD)–associated cardiac arrest, a study found.
Dallas Texas | Image Credit: © SeanPavonePhoto - stock.adobe.com
March 13th 2025

Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most

Christina Mattina
On December 10, 2024, cardiologists, researchers, and value-based care experts gathered in Dallas, Texas, to discuss best practices for implementing advances in cardiology care with a value-based mindset, spanning the care continuum from prevention to treatment.
Pittsburgh, Pennsylvania | Image Credit: © SeanPavonePhoto - stock.adobe.com
March 13th 2025

Reducing Care Fragmentation to Boost CKM Disease Outcomes

Maggie L. Shaw
Discussions at a recent Institute for Value-Based Medicine® event highlighted the interconnected nature of cardio-kidney-metabolic disease and emphasized the need for integrated, patient-centered care.
Phoenix Arizona | Image Credit: © Kevin Ruck - stock.adobe.com
March 12th 2025

Closing the Gaps in Cardiac Care With Technology, Collaboration

Christina Mattina
Cardiologists, primary care physicians, and value-based care leaders convened in Phoenix, Arizona, on November 12, 2024, to share case studies and insights on how to align cardiology with the principles of value-based care, including through the application of digital tools.
Antoine Keller, MD
March 12th 2025

Leveraging AI, Digital Auscultation to Streamline Cardiovascular Diagnoses

Kyle Munz Antoine Keller, MD, FACC, FACS
Advancing technologies have transformed the detection of heart disease and, in turn, streamlined medical processes and relieved burden on health care systems.
Nutritional counseling | Image Credit: © Kittiphan - stock.adobe.com
March 10th 2025

Health Impacts of Health System Implementation of a Food-as-Medicine Strategy

Sarah D. Ronis, MD, PhD Holly Hartman, PhD Ian J. Neeland, MD Anne Leach, MS, RDN, LD Celina Cunanan, MSN, APRN-CNM
This article describes the reach of a Food-as-Medicine strategy implemented by a regional health care system and its impact on adult participants’ cardiometabolic risk factors.
AJMC
March 4th 2025

Real-World Digitally Based Diabetes Management Program Implementation by a Large Employer

Jean M. Abraham, PhD Teresa Ambroz, MPH, RDN Megan Chacon, MPH Renée S. M. Kidney, PhD, MPH Helen M. Parsons, PhD
This study offers new insights to self-insured employers and health plans related to investment in digitally based disease management programs and enrollee engagement.
Medicare Part D. | Image Credit: zimmytws - stock.adobe.com
February 27th 2025

Medicare Part D Spending Trends for Type 2 Diabetes Medications

Cameron Santoro
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising rates of type 2 diabetes and obesity.
Aortic Stenosis remains a serious, worldwide cardiovascular complication | image credit: Pumpala - stock.adobe.come
February 19th 2025

Cardiovascular Magnetic Resonance Highlights Sex-Specific Characteristics in Aortic Stenosis

Kyle Munz
This multicenter study sheds more light on sex-based differences in aortic stenosis (AS) and argues the benefits of using cardiovascular magnetic resonance (CMR) to assess sex-based risks in AS.
Antoine Keller, MD
February 18th 2025

HeartSense's Mission to Reveal, Combat Hidden CV Burdens in Underserved Communities

Kyle Munz Antoine Keller, MD, FACC, FACS
Antoine Keller, MD, founded HeartSense with the purpose of uncovering and addressing the cardiovascular needs of rural, often underserved communities.
Christian Ruff, MD
February 6th 2025

Dr Ruff Explores Mitigating Surgical Bleeding in AFib With Abelacimab

Kyle Munz Christian Ruff, MD
Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.
Conceptualizing reduced cost and increased value | image credit: patpitchaya - stock.adobe.com
February 3rd 2025

Polypill Treatment: A Clinically Effective and Cost-Saving Strategy for CVD Management

Kyle Munz
A polypill for preventing cardiovascular disease has the potential to address health inequities and expand health care access for low-income populations.
Hand holding green apple surrounded by micronutrient names | Image credit: mi_viri – stock.adobe.com
January 28th 2025

Most Patients With Type 2 Diabetes Have Vitamin D Deficiency, Study Suggests

Hayden E. Klein
According to a review of hospital-based cross-sectional studies, almost half the type 2 diabetes population is micronutrient deficient.
Atrial fibrillation | image credit: Uladzlislau - stock.adobe.com
January 22nd 2025

Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial

Kyle Munz Christian Ruff, MD Dan Bloomfield, MD
Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).
AJMC
January 17th 2025

Physiologic Insulin Resensitization Lowers Cost in Patients With Diabetes and Kidney Disease

Zachary Villaverde, BS Roy H. Hinman II, MD Richard M. Grimes, PhD
Patients with diabetes and chronic kidney disease receiving physiologic insulin resensitization had much lower annual costs of care than similar patients not receiving it.
Breast cancer awareness graphic | image credit: ST.art - stock.adobe.com
January 15th 2025

Breast Cancer Stage May Influence Risk of Prevalent CVD

Kyle Munz
Patient outcomes appeared to be more heavily driven by breast cancer stage than delays in diagnosis, researchers found.
GLP-1 | Image Credit: © designua-stock.adobe.com
January 6th 2025

Top GLP-1 Agonists Balance Weight Loss Efficacy, Safety

Maggie L. Shaw
For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL from inception through October 4, 2024.
Dr Yehuda Handelsman
January 3rd 2025

Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care

Brooke McCormick
In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
AJMC Q&A with Ian Neeland, MD | Background image credit: ipopba - stock.adobe.com
January 1st 2025

Overcoming Barriers to Guideline-Directed Cardiometabolic Care

Hayden E. Klein
According to Ian Neeland, MD, strategies like pharmacist-led counseling, patient education programs, and patient assistance initiatives are key to addressing therapeutic inertia.
the top 5 heart failure content of 2024
December 23rd 2024

Top 5 Most-Read Heart Failure Articles of 2024

Hayden E. Klein
Some of the top heart failure research looked at statins and semaglutide for heart failure with preserved ejection fraction, diabetes-related heart failure risks, and the protective cardiovascular effects of COVID-19 vaccination.
FDA website | Image credit: Postmodern Studio – stock.adobe.com
December 20th 2024

FDA Rejects Sotagliflozin for Type 1 Diabetes; Lexicon Shifts Focus

Hayden E. Klein
The FDA issued a complete response letter for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control.
AJMC Q&A with Ian Neeland, MD | Background image credit: ipopba - stock.adobe.com
December 20th 2024

Team-Based CINEMA Program Targets SDOH and Precision Care in Diabetes

Hayden E. Klein
Ian Neeland, MD, discusses the CINEMA program's impact on addressing social determinants of health (SDOH) in Ohio and the importance of precision risk tests to reduce cardiovascular metabolic disease risk.
Dr Yehuda Handelsman
December 20th 2024

Dr Yehuda Handelsman on How DCRM 2.0 Guidelines Refine CRM Disease Management

Brooke McCormick
In this interview, Yehuda Handelsman, MD, highlights key updates to the Diabetes, Cardiorenal, and Metabolic (DCRM) guidelines in DCRM 2.0, shaped by global collaboration and recent clinical insights.
Top 5 conference coverage of 2024
December 17th 2024

Top 5 Conference Coverage of 2024

Hayden E. Klein
Health care conferences this year showcased advancements in treatments for chronic obstructive pulmonary disease and sleep apnea, discussions around health policy and economic research, and more.
AJMC Q&A with Ellen Francis, PhD | Background image credit: ipopba - stock.adobe.com
December 17th 2024

Early Diabetes Screening in Pregnancy: Challenges and Opportunities

Hayden E. Klein
Ellen Francis, PhD, discusses the benefits, challenges, and future implications of implementing earlier diabetes screening for pregnant women.
Ozempic for diabetes | Image credit: mbruxelle – stock.adobe.com
December 17th 2024

Semaglutide Linked to Increased Risk of Rare, Debilitating Eye Condition

Hayden E. Klein
Patients with type 2 diabetes who use semaglutide have more than double the risk of severe optic nerve damage than those who don’t use the drug.
1234>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo